Koers Norda ASA Oslo Bors
Aandelen
NORD
NO0010285190
Biotechnologie & Medisch Onderzoek
Omzet 2021 | 139 mln. 12,69 mln. 11,83 mln. | Omzet 2022 | 128 mln. 11,66 mln. 10,86 mln. | Marktkapitalisatie | 204 mln. 18,57 mln. 17,3 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | 82 mln. 7,47 mln. 6,96 mln. | Nettowinst (verlies) 2022 | 100 mln. 9,11 mln. 8,49 mln. | EV/omzet 2021 | 0,22 x |
Nettoliquiditeiten 2021 | 159 mln. 14,46 mln. 13,47 mln. | Nettoliquiditeiten 2022 | 257 mln. 23,39 mln. 21,8 mln. | EV/omzet 2022 | -0,41 x |
K/w-verhouding 2021 * |
-
| K/w-verhouding 2022 |
-
| Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 6,26% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Frode Westvold
CEO | Chief Executive Officer | - | 08-04-13 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 66 | 20-06-13 | |
Chairman | 52 | 21-06-12 | |
Director/Board Member | - | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-18,16% | 11,03 mld. | |
+58,43% | 3,5 mld. | |
-31,31% | 2,23 mld. | |
-14,31% | 2,16 mld. | |
-26,61% | 1,54 mld. | |
+34,35% | 1,12 mld. | |
-3,28% | 737 mln. | |
-22,75% | 477 mln. | |
-40,20% | 411 mln. |